ZyVersa Therapeutics Inc (NASDAQ: ZVSA) has seen a decline in its stock price by -2.61 in relation to its previous close of 2.30. However, the company has experienced a -2.61% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-22 that Recent evidence links obesity-driven inflammation to diminished brain health and neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases The newly published data show that obesity leads to progressive brain inflammation in a mouse model, and that the proinflammatory processes worsen with prolonged obesity and with increased age This research supports our selection of obesity with associated comorbidities as the lead indication for Inflammasome ASC Inhibitor IC 100 IC 100 inhibits intra- and extracellular ASC and specks associated with multiple types of inflammasomes to attenuate damaging neurologic and systemic inflammation WESTON, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data published in the peer-reviewed journal, Aging Cell, demonstrating that obesity in older adults or prolonged duration of obesity in the younger population resulted in inflammation and suppression of neurotrophic/neuroprotective factors in the brain, indicating that age and duration of obesity are critical risk factors for neurodegenerative diseases.
Is It Worth Investing in ZyVersa Therapeutics Inc (NASDAQ: ZVSA) Right Now?
Company’s 36-month beta value is 0.64.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ZVSA is 1.07M, and currently, short sellers hold a 2.23% ratio of that floaft. The average trading volume of ZVSA on October 22, 2024 was 105.82K shares.
ZVSA’s Market Performance
ZVSA’s stock has seen a -2.61% decrease for the week, with a 3.70% rise in the past month and a -39.30% fall in the past quarter. The volatility ratio for the week is 10.74%, and the volatility levels for the past 30 days are at 6.72% for ZyVersa Therapeutics Inc The simple moving average for the past 20 days is -2.58% for ZVSA’s stock, with a -55.36% simple moving average for the past 200 days.
ZVSA Trading at -11.64% from the 50-Day Moving Average
After a stumble in the market that brought ZVSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.89% of loss for the given period.
Volatility was left at 6.72%, however, over the last 30 days, the volatility rate increased by 10.74%, as shares surge +1.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.68% lower at present.
During the last 5 trading sessions, ZVSA fell by -2.95%, which changed the moving average for the period of 200-days by -74.63% in comparison to the 20-day moving average, which settled at $2.30. In addition, ZyVersa Therapeutics Inc saw -75.11% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ZVSA
Current profitability levels for the company are sitting at:
- -657.66 for the present operating margin
- -0.17 for the gross margin
The net margin for ZyVersa Therapeutics Inc stands at -1399.45. The total capital return value is set at -1.08. Equity return is now at value -152.23, with -84.85 for asset returns.
Currently, EBITDA for the company is -14.41 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 143.83. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.06.
Conclusion
In a nutshell, ZyVersa Therapeutics Inc (ZVSA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
